Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
autologous human tumor-derived HSPPC-96 · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| autologous human tumor-derived HSPPC-96 | DRUG | - |
Pre-Surgery Inclusion Criteria: * Primary-intact resectable renal cell cancer, without known distant metastasis and be scheduled to have surgery with curative intent; * Tumor size greater than or equal to 5 cm OR macroscopic nodes OR renal vein thrombus OR vena cava thrombus by radiologic evaluatio...
Autologous human tumor-derived HSPPC-96 is an investigational cancer vaccine developed for follicular lymphoma and renal cell carcinoma. It has been studied in indolent lymphoma, including small lymphocytic lymphoma, and in kidney cancer. It is not an approved therapy and remains in clinical development.
Autologous human tumor-derived HSPPC-96 targets ADA, classified as an exogenous gene target. This target is the molecular focus of the agent as recorded in its drug profile. The vaccine is designed as a patient-specific treatment derived from the individual's own tumor material.
Agenus Inc., which trades under the ticker AGEN, is the developer of autologous human tumor-derived HSPPC-96. The company has advanced the agent through clinical testing in oncology indications, including lymphoma and renal cell carcinoma.
Autologous human tumor-derived HSPPC-96 is in Phase 2 development. It is an investigational agent and has not been approved by the FDA. A completed Phase 3 trial in renal cell carcinoma also exists, but the drug's current listed development stage is Phase 2.
Autologous human tumor-derived HSPPC-96 has been studied in two completed trials: NCT00081809, a Phase 2 safety and effectiveness study in indolent lymphoma with 35 patients, and NCT00033904, a Phase 3 survival study versus observation in kidney cancer with 650 patients across multiple countries.
Yes, autologous human tumor-derived HSPPC-96 is also known as Oncophage. The Phase 3 renal cell carcinoma trial NCT00033904 was titled as a survival study of Oncophage versus observation. Both names refer to the same investigational agent developed by Agenus Inc.